Who is sponsoring NCT06218004?

NCT06218004 is sponsored by Hairong Liu.

What drugs are being tested in NCT06218004?

Interventions in NCT06218004: Envafolimab combined with chemotherapy.

What condition does NCT06218004 study?

NCT06218004 studies Efficacy and Safety.

Is NCT06218004 still recruiting?

NCT06218004 is currently status unknown. Last updated 23 January 2024.

Last reviewed 2024-01-23 · How we verify

NCT06218004

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Status unknown Phase 2 Last updated 23 January 2024

What this trial tests

Phase 2 trial testing Envafolimab combined with chemotherapy in Efficacy and Safety in 40 participants. Status unknown.

Timeline

25 January 2024

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Hairong Liu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	25 January 2024
Primary completion	31 December 2025
Estimated completion	31 December 2025

Drugs / interventions tested

Envafolimab combined with chemotherapy — full drug profile →

Conditions studied

Efficacy and Safety — all drugs for Efficacy and Safety →

Sponsor

Hairong Liu — full company profile →

Who can join

Adults 18 to 80, any sex, with Efficacy and Safety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective clinical study. The purpose is to explore the efficacy and safety of Envafolimab combined with chemotherapy for neoadjuvant treatment or conversion treatment of locally advanced head and neck squamous cell carcinoma, and to observe the correlation between the immune microenvironment and the efficacy of immune checkpoint inhibitors, genetic changes and the efficacy in head and neck squamous cell carcinoma .

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Efficacy and Safety

Currently open trials in the same condition.

NCT07256522 — Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger · NA · recruiting
NCT07053137 — A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythema · active not recruiting
NCT06732427 — Clinical Study of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment · NA · recruiting
NCT07362693 — A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA · recruiting
NCT06826885 — Safety and Efficacy of IMPT or IMRT for Breast Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06218004 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hairong Liu
Last refreshed: 23 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06218004.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing